NDRA PE Ratio & Valuation,Is NDRA Overvalued

NDRA Relative Valuation

NDRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NDRA is overvalued; if below, it's undervalued.

Historical Valuation

ENDRA Life Sciences Inc (NDRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.34. The fair price of ENDRA Life Sciences Inc (NDRA) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：5.31

Fair

-1.09

0.00

EV/EBITDA

ENDRA Life Sciences Inc. (NDRA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.53. The thresholds are as follows: Strongly Undervalued below -3.50, Undervalued between -3.50 and -2.01, Fairly Valued between 0.95 and -2.01, Overvalued between 0.95 and 2.44, and Strongly Overvalued above 2.44. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.98

EV/EBIT

ENDRA Life Sciences Inc. (NDRA) has a current EV/EBIT of -0.98. The 5-year average EV/EBIT is -1.42. The thresholds are as follows: Strongly Undervalued below -5.71, Undervalued between -5.71 and -3.56, Fairly Valued between 0.73 and -3.56, Overvalued between 0.73 and 2.87, and Strongly Overvalued above 2.87. The current Forward EV/EBIT of -0.98 falls within the Historic Trend Line -Fairly Valued range.

0.00

ENDRA Life Sciences Inc. (NDRA) has a current PS of 0.00. The 5-year average PS is 29.33. The thresholds are as follows: Strongly Undervalued below -112.02, Undervalued between -112.02 and -41.35, Fairly Valued between 100.00 and -41.35, Overvalued between 100.00 and 170.68, and Strongly Overvalued above 170.68. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.26

P/OCF

ENDRA Life Sciences Inc. (NDRA) has a current P/OCF of -1.26. The 5-year average P/OCF is -2.95. The thresholds are as follows: Strongly Undervalued below -10.67, Undervalued between -10.67 and -6.81, Fairly Valued between 0.92 and -6.81, Overvalued between 0.92 and 4.78, and Strongly Overvalued above 4.78. The current Forward P/OCF of -1.26 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

ENDRA Life Sciences Inc. (NDRA) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.84. The thresholds are as follows: Strongly Undervalued below -5.77, Undervalued between -5.77 and -3.30, Fairly Valued between 1.63 and -3.30, Overvalued between 1.63 and 4.09, and Strongly Overvalued above 4.09. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

ENDRA Life Sciences Inc (NDRA) has a current Price-to-Book (P/B) ratio of 23.83. Compared to its 3-year average P/B ratio of 2.94 , the current P/B ratio is approximately 711.82% higher. Relative to its 5-year average P/B ratio of 3.31, the current P/B ratio is about 619.55% higher. ENDRA Life Sciences Inc (NDRA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -181.69%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -125.84% , the current FCF yield is about -100.00% lower.

23.83

P/B

Median3y

2.94

Median5y

3.31

-79.56

FCF Yield

Median3y

-181.69

Median5y

-125.84

Competitors Valuation Multiple

The average P/S ratio for NDRA's competitors is 0.00, providing a benchmark for relative valuation. ENDRA Life Sciences Inc Corp (NDRA) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NDRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NDRA in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ENDRA Life Sciences Inc (NDRA) currently overvalued or undervalued?

What is ENDRA Life Sciences Inc (NDRA) fair value?

NDRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ENDRA Life Sciences Inc (NDRA) is between to according to relative valuation methord.

How does NDRA's valuation metrics compare to the industry average?

What is the current P/B ratio for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?

As of Dec 16 2025, ENDRA Life Sciences Inc (NDRA) has a P/B ratio of 23.83. This indicates that the market values NDRA at 23.83 times its book value.

What is the current FCF Yield for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?

As of Dec 16 2025, ENDRA Life Sciences Inc (NDRA) has a FCF Yield of 0.00%. This means that for every dollar of ENDRA Life Sciences Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?

As of Dec 16 2025, ENDRA Life Sciences Inc (NDRA) has a Forward P/E ratio of -1.09. This means the market is willing to pay $-1.09 for every dollar of ENDRA Life Sciences Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?

As of Dec 16 2025, ENDRA Life Sciences Inc (NDRA) has a Forward P/S ratio of 0.00. This means the market is valuing NDRA at $0.00 for every dollar of expected revenue over the next 12 months.

NDRA Valuation

NDRA Valuation

NDRA Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is ENDRA Life Sciences Inc (NDRA) currently overvalued or undervalued?

What is ENDRA Life Sciences Inc (NDRA) fair value?

How does NDRA's valuation metrics compare to the industry average?

What is the current P/B ratio for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?

What is the current FCF Yield for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?

What is the current Forward P/E ratio for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?

What is the current Forward P/S ratio for ENDRA Life Sciences Inc (NDRA) as of Dec 16 2025?